Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis

Molecular Carcinogenesis

Volumn 25, Issue 3, 1999, Pages 157-163

  Gómez Angelats, Mireia ^a,c   Teeguarden, Justin G ^a,b   Dragan, Yvonne P ^a   Pitot, Henry C ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Apc; Liver tumor; M6p Igf2r; p53; Single strand conformation polymorphism analysis

Indexed keywords

SOMATOMEDIN B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENETIC ANALYSIS; LIVER CARCINOGENESIS; LIVER CARCINOMA; MISSENSE MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; SIMIAN VIRUS 40; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BASE SEQUENCE; FEMALE; GENES, APC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RATS; RATS, INBRED STRAINS; RECEPTOR, IGF TYPE 2;

ANIMALIA; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0344654862     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199907)25:3<157::AID-MC1>3.0.CO;2-8     Document Type: Article

References (59)

1. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
2. Buetow K, Murray JC, Israel JL, et al. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Genetics 1989;86:8852-8856.
3. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992; 52:3674-3678.
4. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-6364.
5. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinoma. Cancer Res 1991;51: 5520-5525.
6. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1 and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-4182.
7. INK4 in hepatocellular carcinoma. Hepatology 1996;24: 575-579.
8. De Souza A, Hankins GR, Washington MK, Orton TC, Jirtle RL. MP6/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11:447-449.
9. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: A potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995;55: 4717-4721.
10. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58:2524-2527.
11. Greenblatt MS, Bennett M, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
12. Nishida N, Yoshihiro F, Kokuryo H, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-372.
13. Kasai Y, Takeda S, Takagi H. Pathogenesis of HCC: A review from the viewpoint of molecular analysis. Semin Surg Oncol 1996;12(3):155-159.
14. Hsu IC, Metcalf RA, Sun T, Welsh JA, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428.
15. Smith M, Yeleswarapu L, Locker J, Lombardi B. Expression of p53 mutant protein(s) in diethylnitrosamine-induced foci of enzyme altered hepatocytes in male Fischer 344 rats. Carcinogenesis 1991;12:1137-1141.
16. Smith M, Yeleswaraou L, Scalamogna P, Locker J, Lombardi B. p53 mutation in hepatocellular carcinomas induced by a choline-devoid diet in male Fischer 344 rats. Carcinogenesis 1993;14:503-510.
17. Lilleberg S, Cabone MA, Raju N, Wagner L, Kier L. Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1. Mol Carcinog 1992;6:159-172.
18. Hulla J, Chen Z, Eaton DL. Aflatoxin B1-induced rat hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res 1993;53:9-11.
19. Tokusashi Y, Fukuda I, Ogawa K. Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens. Mol Carcinog 1994;10:45-51.
20. Calvert R, Tashiro Y, Buzard G, Diwan B, Weghorst C. Lack of p53 point mutations in chemically induced mouse hepatoblastomas: An end-stage, highly malignant hepatocellular carcinoma. Cancer Lett 1995;95:175-180.
21. Tamano S, Ward JM, Diwan BA, et al. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. Carcinogenesis 1996;17:2477-2486.
22. Barbin A, Froment O, Boivin S, et al. p53 gene mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res 1997;57:1695-1698
23. Sipowicz M, Weghorst C, Shiao Y, et al. Lack of p53 and ras mutations in Helicobacter hepaticus induced liver tumors in A/JCr mice. Carcinogenesis 1997;18:233-236.
24. Hartshorn MA, Scott CD, Baxter RC. Immunofluorescent localization of type II insulin-like growth factor receptor in rat liver and hepatoma cells. J Endocrinol 1989;121: 221-227.
25. Joslyn G, Carlson M, Thiliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601-613.
26. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
27. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-233.
28. Powell S, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-237.
29. Oda H, lami Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of APC gene in sporadic hepatoblastomas. Cancer Res 1996;56:3320-3323.
30. Giardello FM, Petersen GM, Brensinger JD, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996;39:867-869.
31. Kurahashi H, Takami K, Oue T, et al. Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res 1995;55: 5007-5011.
32. Dragan YP, Sargent L, Xu YD, Xu YH, Pitot HC. The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc Soc Exp Biol Med 1993;202:16-24.
33. Pitot HC, Dragan Y. Stage of tumor progression, progressor agents, and human risk. Proc Soc Exp Biol Med 1993; 202:27-43.
34. Hully J, Su Y, Lohse J, et al. Transgenic hepatocarcinogenesis in the rat. Am J Pathol 1994;145:384-397.
35. Sargent L, Dragan Y, Xu Y, Sattler G, Wiley J, Pitot HC. Karyotypic changes in a multistage model of chemical hepatocarcinogenesis. Cancer Res 1996;56:2985-2991.
36. Sargent L, Dragan Y, Babcock K, Wiley J, Klaunig J, Pitot HC. Cytogenetic analysis of three rat liver epithelial cell lines (WBneo, WBHa-ras and WBraslla) and correlation of an early chromosomal alteration with insulin-like growth factor II expression. Cancer Res 1996;56:2992-2997.
37. Sargent L, Dragan Y, Sattler G, Xu Y, Wiley J, Pitot HC. Specific chromosomal changes in albumin simian virus 40 T-antigen transgenic rat liver neoplasms. Cancer Res 1997; 57:3451-3456.
38. Maronpot RR, Montgomery CA Jr, Boorman GA, McConell EE. National Toxicology Program nomenclature for hepatoproliferative lesions of rats. Toxicol Pathol 1996;14: 263-273.
39. Sambrook J, Fritsch EF, Maniatis T, editors. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Spring Harbor Laboratory Press; 1989.
40. Bulera S, Haas M, Sattler C, Li Y, Pitot HC. Cell lines with heterogeneous phenotypes result from a single isolation of albumin-sv40 T-Antigen transgenic rat hepatocytes. Hepatology 1997;25;1192-1203.
41. Hulla JE, Schneider RP. Structure of the rat p53 tumor suppressor gene. Nucleic Acids Res 1993;21:713-717.
42. Kakiuchi H, Watanabe M, Ushijima T, et al. Specific 5′-GGGA-3′ to 5′-GGA-3′ mutation of the Apc gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine. Proc Natl Acad Sci USA 1995;92: 910-914
43. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5: 874-879.
44. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1984;12:387-395.
45. Gimenez-Conti IB, Lebate M, Liu F, Ostendorff E. p53 alterations in chemically induced cheek-pouch lesions. Mol Carcinog 1996;16:197-202.
46. Haas JH, Pitot HC. Characterization of rare p53 mutants from carcinogen-treated albumin-simian virus 40 T-antigen transgenic rats. Mol Carcinog 1998;21:128-134.
47. Kress SK, Schweizer J, Lohrke H, Bauer-Hofmann R, Schwarz M. p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol Carcinog 1992;6: 148-158.
48. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas. Cancer Res 1994;54:3864-3867.
49. Clurman B, Groudine M. Killer in search of a motive. Nature 1997;389:122-123.
50. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389:191-194.
51. Bian J, Sun Y. p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family. Proc Natl Acad Sci USA 1997;94:14573-14578.
52. Olson DC, Levine AJ. The properties of p53 proteins selected for the loss of suppression of transformation. Cell Growth Differ 1994;5:61-71.
53. Cho Y, Gorina S, Jeffrey P, Pavletich N. Crystal structure of a p53 tumor-DNA complex: Understanding tumorigenic mutations. Science 1994;265:346-355.
54. Moser GJ, Wolf DC, Harden R, et al. Cell proliferation and regulation of negative growth factors in mouse liver foci. Carcinogenesis 1996;17:1835-1840.
55. Yamada T, De Souza TA, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-10355.
56. Barlow DP, Stoger R, Herrmann BG, Saito K, Schweifer N. The mouse insulin-like growth factor type 2 receptor is imprinted and closely linked to the Tme locus. Nature 1991; 351:153-155.
57. Stoger R, Kubicka P, Liu C, et al. Maternal-specific methylation of the imprinted mouse lgf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993;73:61-71.
58. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262: 1734-1737.
59. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β-catenin. Science 1993;262: 1731-1733.